Kamada, Baxter enter distribution and manufacturing agreement for Glassia Alpha-1 Antitrypsin Product

Kamada, Ltd. (TASE: KMDA), a biopharmaceutical company engaged in development, production and marketing of specialty life-saving therapeutics ("Kamada") and Baxter International Inc., a global, diversified healthcare company ("Baxter") announced today that they have entered into an exclusive distribution and manufacturing agreement for Kamada's liquid, ready to use, intravenous Alpha-1 Antitrypsin Product for the treatment of hereditary Alpha-1 Antitrypsin Deficiency approved by the USFDA on July 1st, 2010 for marketing under the trade name "Glassia™". The companies have also entered into a Technology Sharing agreement for the manufacturing of liquid AAT at Baxter facility using Kamada's proprietary and patented technology.

Under the terms of the agreements, Baxter will be responsible for marketing and distribution of Glassia™ in the US, Canada, Australia and New Zealand. Within the scope of the agreements, Kamada will receive milestone payments of $45 million including an upfront payment of $20 million. Furthermore, Kamada will also be eligible to receive up to $25 million in aggregate payments upon the achievement of certain milestones. Baxter has a commitment to purchase minimum quantities of Glassia™ in the range of $60 million that could reach $110 million during the first five years of the agreements. Kamada will also be eligible to receive significant royalty payments on net sales of the product produced by Baxter.

The distribution rights and the licensing agreement do not include the Inhaled version of Kamada's AAT product, currently in phase 2-3 clinical trial in Europe. Nevertheless, under the terms of the agreements, both sides will examine additional cooperation opportunities for the inhaled product.

Under this engagement, Baxter will serve as Kamada's exclusive distributor for Glassia™ in the US.

David Tsur, Chief Executive Officer of Kamada Ltd., stated, "This is a great achievement for Kamada. Baxter is one of the world's largest biopharmaceuticals companies and has a strong history of creating and establishing market-leading brands, a track record that makes Baxter our ideal commercial partner for Glassia™. The strategic cooperation with Baxter is expected to enable Kamada to reach significantly larger sales volume in the US market with greater profitability margins. The cooperation with Baxter will enable Kamada financial independence and firmness needed for facilitating the development of the next generation product, the Inhaled AAT."

Source:

Kamada, Ltd. and Baxter International Inc.,

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2019, June 18). Kamada, Baxter enter distribution and manufacturing agreement for Glassia Alpha-1 Antitrypsin Product. News-Medical. Retrieved on April 06, 2020 from https://www.news-medical.net/news/20100825/Kamada-Baxter-enter-distribution-and-manufacturing-agreement-for-Glassia-Alpha-1-Antitrypsin-Product.aspx.

  • MLA

    Baxter International Inc.. "Kamada, Baxter enter distribution and manufacturing agreement for Glassia Alpha-1 Antitrypsin Product". News-Medical. 06 April 2020. <https://www.news-medical.net/news/20100825/Kamada-Baxter-enter-distribution-and-manufacturing-agreement-for-Glassia-Alpha-1-Antitrypsin-Product.aspx>.

  • Chicago

    Baxter International Inc.. "Kamada, Baxter enter distribution and manufacturing agreement for Glassia Alpha-1 Antitrypsin Product". News-Medical. https://www.news-medical.net/news/20100825/Kamada-Baxter-enter-distribution-and-manufacturing-agreement-for-Glassia-Alpha-1-Antitrypsin-Product.aspx. (accessed April 06, 2020).

  • Harvard

    Baxter International Inc.. 2019. Kamada, Baxter enter distribution and manufacturing agreement for Glassia Alpha-1 Antitrypsin Product. News-Medical, viewed 06 April 2020, https://www.news-medical.net/news/20100825/Kamada-Baxter-enter-distribution-and-manufacturing-agreement-for-Glassia-Alpha-1-Antitrypsin-Product.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
You might also like... ×
Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial